Page last updated: 2024-08-26

sr141716 and glucagon

sr141716 has been researched along with glucagon in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (66.67)	29.6817
2010's	1 (33.33)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Cani, PD; Delzenne, NM; Lambert, DM; Montoya, ML; Neyrinck, AM	1
Debaty, I; Halimi, S; Muller, M; Villaret, L	1
Bahekar, R; Jain, MR; Joharapurkar, AA; Kshirsagar, SG; Patel, KN; Patel, V; Srivastava, BK	1

Reviews

1 review(s) available for sr141716 and glucagon

Article	Year
[New therapies for type 2 diabetes: what place for incretin-based agents and rimonabant compared to the previous ones?]. La Revue de medecine interne, 2008, Volume: 29, Issue:11 Topics: Administration, Oral; Diabetes Mellitus, Type 2; Glucagon; Glycoside Hydrolase Inhibitors; Humans; Hyperglycemia; Hypoglycemic Agents; Incretins; Metabolic Syndrome; Metformin; Piperidines; Pyrazoles; Rimonabant; Safety; Sulfonylurea Compounds; Thiazolidinediones	2008

Article

Year

[New therapies for type 2 diabetes: what place for incretin-based agents and rimonabant compared to the previous ones?].

La Revue de medecine interne, 2008, Volume: 29, Issue:11

Topics: Administration, Oral; Diabetes Mellitus, Type 2; Glucagon; Glycoside Hydrolase Inhibitors; Humans; Hyperglycemia; Hypoglycemic Agents; Incretins; Metabolic Syndrome; Metformin; Piperidines; Pyrazoles; Rimonabant; Safety; Sulfonylurea Compounds; Thiazolidinediones

2008

Other Studies

2 other study(ies) available for sr141716 and glucagon

Article	Year
Potential modulation of plasma ghrelin and glucagon-like peptide-1 by anorexigenic cannabinoid compounds, SR141716A (rimonabant) and oleoylethanolamide. The British journal of nutrition, 2004, Volume: 92, Issue:5 Topics: Animals; Appetite Regulation; Blood Glucose; Blotting, Western; Cannabinoids; Eating; Endocannabinoids; Ghrelin; Glucagon; Glucagon-Like Peptide 1; Male; Oleic Acids; Peptide Fragments; Peptide Hormones; Piperidines; Protein Precursors; Pyrazoles; Rats; Rats, Wistar; Receptors, Drug; Rimonabant	2004
Cannabinoid receptor 1 antagonist treatment induces glucagon release and shows an additive therapeutic effect with GLP-1 agonist in diet-induced obese mice. Canadian journal of physiology and pharmacology, 2014, Volume: 92, Issue:12 Topics: Animals; Anti-Obesity Agents; Blood Glucose; Body Weight; Diet, High-Fat; Drug Synergism; Eating; Exenatide; Glucagon; Glucagon-Like Peptide 1; Insulin Resistance; Male; Mice, Inbred C57BL; Mice, Obese; Obesity; Peptides; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Venoms	2014

Article

Year

Potential modulation of plasma ghrelin and glucagon-like peptide-1 by anorexigenic cannabinoid compounds, SR141716A (rimonabant) and oleoylethanolamide.

The British journal of nutrition, 2004, Volume: 92, Issue:5

Topics: Animals; Appetite Regulation; Blood Glucose; Blotting, Western; Cannabinoids; Eating; Endocannabinoids; Ghrelin; Glucagon; Glucagon-Like Peptide 1; Male; Oleic Acids; Peptide Fragments; Peptide Hormones; Piperidines; Protein Precursors; Pyrazoles; Rats; Rats, Wistar; Receptors, Drug; Rimonabant

2004

Cannabinoid receptor 1 antagonist treatment induces glucagon release and shows an additive therapeutic effect with GLP-1 agonist in diet-induced obese mice.

Canadian journal of physiology and pharmacology, 2014, Volume: 92, Issue:12

Topics: Animals; Anti-Obesity Agents; Blood Glucose; Body Weight; Diet, High-Fat; Drug Synergism; Eating; Exenatide; Glucagon; Glucagon-Like Peptide 1; Insulin Resistance; Male; Mice, Inbred C57BL; Mice, Obese; Obesity; Peptides; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Venoms

2014